Literature DB >> 15883783

Gene expression profiles of different clinical stages of colorectal carcinoma: toward a molecular genetic understanding of tumor progression.

Jan Friederichs1, Robert Rosenberg, Joerg Mages, Klaus-Peter Janssen, Christian Maeckl, Hjalmar Nekarda, Bernhard Holzmann, Joerg-Ruediger Siewert.   

Abstract

BACKGROUND AND AIMS: Colorectal cancer is one of the leading causes of cancer deaths in the Western world. A better understanding of the development and progression of colorectal carcinoma is needed to define novel targets and strategies for treatment. PATIENTS/
METHODS: Gene expression profiles were determined for primary tumors of 10 locally restricted (T3N0M0), 8 lymphatically metastasized (T3N+M0), 7 systemically metastasized (T3N+M1) colorectal carcinomas, and 6 specimens of normal colorectal tissue by histology-guided oligonucleotide microarray analysis.
RESULTS: A total of 1,995 genes were differently regulated in primary tumors of colorectal carcinoma compared with normal colorectal tissue. Besides common features of dedifferentiation and different expression of genes involved in cell division, cell adhesion, angiogenesis, signal transduction and metabolism we observed a deregulation of genes with an as yet unclear function. We identified 126 genes that were subsequently up- and 204 genes down-regulated during tumor progression. Furthermore, we found a cluster of five genes exclusively up-regulated in primary tumors of systemically metastasized colorectal carcinomas. A comparison of locally restricted (T3N0M0) and systemically metastasized (T3N+M1) primary tumors showed 50 deregulated genes with a massive down-regulation of immune-modulatory genes in primary tumors of systemically metastasized carcinomas. Primary tumors of lymphatically (T3N+M0) and systemically metastasized (T3N+M1) carcinomas differed in the expression of 19 genes.
CONCLUSION: These results provide an additional step toward the identification of crucial genes for the progression of colorectal cancer and the identification of novel treatment targets or strategies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15883783     DOI: 10.1007/s00384-004-0722-1

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  30 in total

1.  Detection of high incidence of K-ras oncogenes during human colon tumorigenesis.

Authors:  K Forrester; C Almoguera; K Han; W E Grizzle; M Perucho
Journal:  Nature       Date:  1987 May 28-Jun 3       Impact factor: 49.962

2.  Broad patterns of gene expression revealed by clustering analysis of tumor and normal colon tissues probed by oligonucleotide arrays.

Authors:  U Alon; N Barkai; D A Notterman; K Gish; S Ybarra; D Mack; A J Levine
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-08       Impact factor: 11.205

3.  Rho GTPases are over-expressed in human tumors.

Authors:  G Fritz; I Just; B Kaina
Journal:  Int J Cancer       Date:  1999-05-31       Impact factor: 7.396

4.  Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling.

Authors:  Deepak Agrawal; Tingan Chen; Rosalyn Irby; John Quackenbush; Ann F Chambers; Marianna Szabo; Alan Cantor; Domenico Coppola; Timothy J Yeatman
Journal:  J Natl Cancer Inst       Date:  2002-04-03       Impact factor: 13.506

5.  Role of stromal collagen in immunomodulation and prognosis of advanced gastric carcinoma.

Authors:  Satoshi Ohno; Mitsuo Tachibana; Toshiyuki Fujii; Shuhei Ueda; Hirofumi Kubota; Naofumi Nagasue
Journal:  Int J Cancer       Date:  2002-02-20       Impact factor: 7.396

Review 6.  Chronic inflammatory bowel disease and cancer.

Authors:  C Pohl; A Hombach; W Kruis
Journal:  Hepatogastroenterology       Date:  2000 Jan-Feb

Review 7.  Never say never. The NIMA-related protein kinases in mitotic control.

Authors:  Matthew J O'Connell; Michael J E Krien; Tony Hunter
Journal:  Trends Cell Biol       Date:  2003-05       Impact factor: 20.808

8.  Classification of Dukes' B and C colorectal cancers using expression arrays.

Authors:  Casper Møller Frederiksen; Steen Knudsen; Søren Laurberg; Torben F Ørntoft
Journal:  J Cancer Res Clin Oncol       Date:  2003-05-15       Impact factor: 4.553

Review 9.  CSE1L/CAS: its role in proliferation and apoptosis.

Authors:  P Behrens; U Brinkmann; A Wellmann
Journal:  Apoptosis       Date:  2003-01       Impact factor: 4.677

10.  Gene expression in colorectal cancer.

Authors:  Karin Birkenkamp-Demtroder; Lise Lotte Christensen; Sanne Harder Olesen; Casper M Frederiksen; Päivi Laiho; Lauri A Aaltonen; Søren Laurberg; Flemming B Sørensen; Rikke Hagemann; Torben F ØRntoft
Journal:  Cancer Res       Date:  2002-08-01       Impact factor: 12.701

View more
  20 in total

1.  Mutated KRAS results in overexpression of DUSP4, a MAP-kinase phosphatase, and SMYD3, a histone methyltransferase, in rectal carcinomas.

Authors:  Jochen Gaedcke; Marian Grade; Klaus Jung; Jordi Camps; Peter Jo; Georg Emons; Anastasia Gehoff; Ulrich Sax; Markus Schirmer; Heinz Becker; Tim Beissbarth; Thomas Ried; B Michael Ghadimi
Journal:  Genes Chromosomes Cancer       Date:  2010-11       Impact factor: 5.006

2.  Reduced lymph node yield in rectal carcinoma specimen after neoadjuvant radiochemotherapy has no prognostic relevance.

Authors:  Dietrich Doll; Ralf Gertler; Matthias Maak; Jan Friederichs; Karen Becker; Hans Geinitz; Monika Kriner; Hjalmar Nekarda; Jörg R Siewert; Robert Rosenberg
Journal:  World J Surg       Date:  2009-02       Impact factor: 3.352

3.  Differential expression of the chemokines GRO-2, GRO-3, and interleukin-8 in colon cancer and their impact on metastatic disease and survival.

Authors:  Dietrich Doll; Larissa Keller; Matthias Maak; Anne-Laure Boulesteix; Jörg R Siewert; Bernhard Holzmann; Klaus-Peter Janssen
Journal:  Int J Colorectal Dis       Date:  2010-02-17       Impact factor: 2.571

Review 4.  Genomic markers for decision making: what is preventing us from using markers?

Authors:  Vicky M Coyle; Patrick G Johnston
Journal:  Nat Rev Clin Oncol       Date:  2009-12-15       Impact factor: 66.675

5.  Clinical applications of gene expression in colorectal cancer.

Authors:  Elrasheid A H Kheirelseid; Nicola Miller; Kah Hoong Chang; Mary Nugent; Michael J Kerin
Journal:  J Gastrointest Oncol       Date:  2013-06

6.  Identification of differential proteins in colorectal cancer cells treated with caffeic acid phenethyl ester.

Authors:  Yu-Jun He; Wan-Ling Li; Bao-Hua Liu; Hui Dong; Zhi-Rong Mou; Yu-Zhang Wu
Journal:  World J Gastroenterol       Date:  2014-09-07       Impact factor: 5.742

7.  Bifidobacterium bifidum PRL2010 modulates the host innate immune response.

Authors:  Francesca Turroni; Valentina Taverniti; Patricia Ruas-Madiedo; Sabrina Duranti; Simone Guglielmetti; Gabriele Andrea Lugli; Laura Gioiosa; Paola Palanza; Abelardo Margolles; Douwe van Sinderen; Marco Ventura
Journal:  Appl Environ Microbiol       Date:  2013-11-15       Impact factor: 4.792

8.  Investigation of the expression levels of CPEB4, APC, TRIP13, EIF2S3, EIF4A1, IFNg, PIK3CA and CTNNB1 genes in different stage colorectal tumors

Authors:  Zafer Söylemez; Evrim Suna Arıkan; Mustafa Solak; Yüksel Arıkan; Çiğdem Tokyol; Hüseyin Şeker
Journal:  Turk J Med Sci       Date:  2021-04-30       Impact factor: 0.973

9.  Modeling oncogenic signaling in colon tumors by multidirectional analyses of microarray data directed for maximization of analytical reliability.

Authors:  Magdalena Skrzypczak; Krzysztof Goryca; Tymon Rubel; Agnieszka Paziewska; Michal Mikula; Dorota Jarosz; Jacek Pachlewski; Janusz Oledzki; Jerzy Ostrowski; Jerzy Ostrowsk
Journal:  PLoS One       Date:  2010-10-01       Impact factor: 3.240

10.  Comparative profiling of primary colorectal carcinomas and liver metastases identifies LEF1 as a prognostic biomarker.

Authors:  Albert Y Lin; Mei-Sze Chua; Yoon-La Choi; William Yeh; Young H Kim; Raymond Azzi; Gregg A Adams; Kristin Sainani; Matt van de Rijn; Samuel K So; Jonathan R Pollack
Journal:  PLoS One       Date:  2011-02-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.